Professor Benjamin Solomon MBBS, PhD, FRACP, FAHMS is a medical oncologist focused on clinical and translational research for lung cancer. He heads the lung Medical Oncology Service at Peter MacCallum Cancer Centre in Melbourne, Australia. His clinical trial work focuses on the identification of novel therapies for lung cancer including novel targeted therapy and immunotherapy approaches. He has been involved in clinical trials with novel inhibitors of ALK, ROS1, NTRK, BRAF, cMET, RET and KRAS including the phase I though 3 trials with the ALK TKIs leading to approvals of crizotinib and lorlatinib and the approval of adjuvant alectinib. He has over 250 peer-reviewed publications with over 50,0000 citations and has been named a Clarivate Highly Cited Researcher (2019-2024). He is a founding board member of the Thoracic Oncology Group of Australasia and is a Board Member of the Cancer Council of Victoria and the International Association for the study of Lung Cancer (IASLC).